| Project/Area Number |
15K10258
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
佃 和憲 岡山大学, 大学病院, 講師 (20346430)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TOYOOKA Shinichi 岡山大学, 医歯薬学総合研究科, 教授 (30397880)
SOU Junichi 岡山大学, 大学病院, 講師 (90559890)
YAMAMOTO Hiromasa 岡山大学, 大学病院, 助教 (40467733)
|
|---|
| Research Collaborator |
SUZAWA Ken
OTSUKA Tomoaki
CHEN Haiyang
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 肺癌 / EGFR-TKI耐性 / ABCB1阻害剤 / Elacrida / 上皮成長因子受容体チロシンキナーゼ阻害剤耐性 |
|---|
| Outline of Final Research Achievements |
One of the most pressing needs for NSCLC with EGFR mutation is to overcome the acquired resistance to EGFR-TKI targeted therapy. We established EGFR-TKI resistant HCC827, HCC4006 and H1299 cells harboring stem cell-like properties. In these EGFR-TKI resistant cells, we detected overexpression of ABCB1 mRNA. Restoration of sensitivity to chemotherapeutic agent(docetaxel) was observed by knocking down of ABCB1 expression. We further observed the usefulness of 3rd generation ABCB1 inhibitor “Elacrida” to EGFR-TKI resistant lung cancer cells harboring stem cell-like properties.
|
